Paindrainer, a Swedish digital therapeutics company, has closed a €550,000 funding round from a mix of existing and new shareholders, according to an announcement from the Lund-based firm. The capital injection marks a significant milestone for the healthtech startup as it prepares to expand its operations and strengthen its commercial presence in key markets.
The funding round was supported by existing shareholder Almi Invest alongside new backer Tramontane Invest, along with additional existing and new shareholders who participated in the share issue transaction. The company plans to deploy the fresh capital toward three primary objectives: scaling its commercial operations in the United States, bringing its newest product offering to market, and bolstering its internal team.
Expanding the Digital Therapeutics Portfolio
Paindrainer develops artificial intelligence-powered digital platforms designed to address chronic pain management across patient populations. The company’s existing offering, the PD Care System, represents its flagship product in the digital therapeutics space. Building on this foundation, the company is preparing to launch Relivra, a new product leveraging proprietary Artificial Neural Networks technology.
The timing of this funding round reflects broader market momentum in the digital health sector. Erik Frick, Chief Executive Officer of Paindrainer, expressed enthusiasm about the successful capital raise, stating: “Having completed a share issue transaction in the current market with support from both existing and new owners feels fantastic. It shows the growing interest in these types of third-generation digital companies, and it enables us to continue our highly important commercialization and start to grow our operations.”
US Market Opportunity
The allocation of funds toward American market entry underscores the company’s strategic focus on the world’s largest healthcare market. Chronic pain represents a substantial healthcare challenge globally, with millions of patients seeking effective management solutions. Digital therapeutics have emerged as a complementary approach to traditional treatment methods, offering scalable interventions that can be delivered remotely to patients.
European Momentum in Digital Health
Paindrainer’s funding round reflects the continued vitality of the European digital health ecosystem. Swedish companies in particular have established a strong track record in healthtech innovation, with support from institutional investors and government-backed funding bodies like Almi Invest. The involvement of both public and private capital in this round demonstrates confidence in the company’s business model and market opportunity.
The digital therapeutics sector across Europe continues to attract investor interest as healthcare systems seek cost-effective solutions for chronic disease management. Companies developing AI-enabled platforms for therapeutic applications are increasingly attracting capital from specialized healthtech investors, signaling a maturing market segment within the broader European startup landscape.